Robert Daly

1.2k total citations
22 papers, 866 citations indexed

About

Robert Daly is a scholar working on Surgery, Cellular and Molecular Neuroscience and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Robert Daly has authored 22 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 6 papers in Cellular and Molecular Neuroscience and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robert Daly's work include Neuropeptides and Animal Physiology (6 papers), Receptor Mechanisms and Signaling (4 papers) and Cardiovascular, Neuropeptides, and Oxidative Stress Research (3 papers). Robert Daly is often cited by papers focused on Neuropeptides and Animal Physiology (6 papers), Receptor Mechanisms and Signaling (4 papers) and Cardiovascular, Neuropeptides, and Oxidative Stress Research (3 papers). Robert Daly collaborates with scholars based in United States, United Kingdom and Canada. Robert Daly's co-authors include J. Paul Hieble, Benjamin Weiss, Mary S. Barnette, Aaron T. Gerds, Jennifer Callahan, Jason Gotlib, Srđan Verstovšek, Jack W. Singer, Anita Szőke and Tanya Granston and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and The American Journal of Cardiology.

In The Last Decade

Robert Daly

22 papers receiving 842 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Daly United States 15 362 243 241 196 169 22 866
Irina V Kaplan United States 12 197 0.5× 182 0.7× 137 0.6× 133 0.7× 57 0.3× 25 1.0k
Slobodan Apostolski Serbia 18 270 0.7× 47 0.2× 119 0.5× 287 1.5× 58 0.3× 63 1.4k
Mariko Yagi Japan 21 1.1k 3.1× 44 0.2× 190 0.8× 99 0.5× 225 1.3× 66 1.5k
Jiaqing Pang United States 17 247 0.7× 313 1.3× 135 0.6× 23 0.1× 113 0.7× 37 804
Lindsay Coleman United Kingdom 12 733 2.0× 159 0.7× 23 0.1× 69 0.4× 198 1.2× 17 1.4k
Li Gao China 20 596 1.6× 276 1.1× 80 0.3× 108 0.6× 18 0.1× 65 1.2k
Shogo Tamura Japan 15 173 0.5× 236 1.0× 52 0.2× 46 0.2× 79 0.5× 54 699
Hui Xiong China 17 652 1.8× 16 0.1× 239 1.0× 126 0.6× 123 0.7× 116 1.0k
Aleksandra Stojanović Serbia 13 252 0.7× 277 1.1× 45 0.2× 30 0.2× 140 0.8× 37 753
Oscar Suzuki United States 15 539 1.5× 30 0.1× 53 0.2× 130 0.7× 140 0.8× 25 817

Countries citing papers authored by Robert Daly

Since Specialization
Citations

This map shows the geographic impact of Robert Daly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Daly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Daly more than expected).

Fields of papers citing papers by Robert Daly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Daly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Daly. The network helps show where Robert Daly may publish in the future.

Co-authorship network of co-authors of Robert Daly

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Daly. A scholar is included among the top collaborators of Robert Daly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Daly. Robert Daly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mascarenhas, John, Ronald Hoffman, Moshe Talpaz, et al.. (2018). Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology. 4(5). 652–652. 255 indexed citations
3.
4.
Belada, David, Pencho Georgiev, Shaker R. Dakhil, et al.. (2016). Pixantrone–Rituximab Versus Gemcitabine–Rituximab In Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. Future Oncology. 12(15). 1759–1768. 14 indexed citations
5.
Dyke, Cornelius M., et al.. (2007). Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. Journal of Cardiovascular Pharmacology and Therapeutics. 12(1). 54–60. 7 indexed citations
6.
Montross, Lori P., Ann‐Marie Yamada, Laurie A. Lindamer, et al.. (2005). Tri-ethnic variations of co-morbid substance and alcohol use disorders in schizophrenia. Schizophrenia Research. 79(2-3). 297–305. 21 indexed citations
7.
Bunch, T. Jared, Abhishek Chandra, Keiji Ujino, et al.. (2005). Prevalence, Pathophysiology, and Clinical Significance of Post-heart Transplant Atrial Fibrillation and Atrial Flutter. The Journal of Heart and Lung Transplantation. 25(1). 53–60. 65 indexed citations
8.
Murphy, Joseph G., R. Scott Wright, Ihor Gussak, et al.. (2003). The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease. American Journal of Cardiovascular Drugs. 3(2). 101–112. 13 indexed citations
9.
Billheimer, Jeffrey T., Ira B. Dicker, Richard Wynn, et al.. (2002). Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 99(10). 3540–3546. 47 indexed citations
10.
11.
Alexander, Karen P., L. Kristin Newby, Anne S. Hellkamp, et al.. (2001). Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. Journal of the American College of Cardiology. 38(1). 1–7. 90 indexed citations
12.
O’Connor, Christopher M., Wendy A. Gattis, Anne S. Hellkamp, et al.. (2001). Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). The American Journal of Cardiology. 88(5). 541–546. 13 indexed citations
13.
Daly, Robert, et al.. (1990). Studies on the Mechanism of Neuropeptide Y Induced Potentiation of Neurogenic Vasoconstriction in the Isolated Rabbit Ear Artery. American Journal of Hypertension. 3(10_Pt_1). 796–799. 6 indexed citations
14.
Michel, Martin C., Eberhard Schlicker, Klaus Fink, et al.. (1990). Distinction of NPY receptors in vitro and in vivo. I. NPY-(18-36) discriminates NPY receptor subtypes in vitro. American Journal of Physiology-Endocrinology and Metabolism. 259(1). E131–E139. 34 indexed citations
15.
Daly, Robert, et al.. (1989). The Effect of Age on Presynaptic Alpha2 Adrenoceptor Autoregulation of Norepinephrine Release. Journal of Gerontology. 44(3). B59–B66. 22 indexed citations
16.
Hieble, J. Paul, et al.. (1989). Effects of neuropeptide Y on the response of isolated blood vessels to norepinephrine and sympathetic field stimulation.. Journal of Pharmacology and Experimental Therapeutics. 250(2). 523–528. 27 indexed citations
17.
Daly, Robert, et al.. (1988). The role of neuropeptide Y in vascular sympathetic neurotransmission may be enhanced in hypertension. Journal of Hypertension. 6(4). S535–538. 18 indexed citations
18.
Hieble, J. Paul, Robert Ruffolo, & Robert Daly. (1988). Involvement of vascular endothelium in the potentiation of vasoconstrictor responses by neuropeptide Y. Journal of Hypertension. 6(4). S239–242. 6 indexed citations
19.
Daly, Robert, et al.. (1988). Effects of age on neurotransmission at the cardiac sympathetic neuroeffector junction.. Journal of Pharmacology and Experimental Therapeutics. 245(3). 798–803. 33 indexed citations
20.
Daly, Robert & J. Paul Hieble. (1987). Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. European Journal of Pharmacology. 138(3). 445–446. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irina V Kaplan Breakdown of academic impact, for papers by Slobodan Apostolski Breakdown of academic impact, for papers by Mariko Yagi Breakdown of academic impact, for papers by Jiaqing Pang Breakdown of academic impact, for papers by Lindsay Coleman Breakdown of academic impact, for papers by Li Gao Breakdown of academic impact, for papers by Shogo Tamura Breakdown of academic impact, for papers by Hui Xiong Breakdown of academic impact, for papers by Aleksandra Stojanović Breakdown of academic impact, for papers by Oscar Suzuki
Rankless by CCL
2026